Latest filing published 13 Nov 2026 for Septerna, Inc., €286k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +293.9%Entry US$6.68 · Close at T+365 US$26.31
- +351.9%Entry US$6.43 · Close at T+365 US$29.06
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Alan Ezekowitz: trading record in brief
Alan Ezekowitz has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Septerna, Inc. and Fulcrum Therapeutics, Inc. Over a trading history stretching from 4 March 2025 to 11 November 2026, the count stands at 12 filings.
On the open market, the record shows 4 purchases worth €568k and 8 sales worth €3.6M. Netting one side against the other leaves €3.0M of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Since January 2026: no purchases and 8 sales on the market.
A typical purchase (the median) is worth €146k. Clusters matter here: 4 out of 4 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 100% of cases; the median change was +63.6%. Past outcomes like these are no guarantee of what comes next.
The newest entry dates from 13 November 2026: an open-market sale of €286k, in Septerna, Inc. The latest purchase dates back some time: it was published 617 days ago, on 10 March 2025. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Alan Ezekowitz
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,939 shares@ US$46.005Common StockSEC:0001193125-26-461248:0
- 13,201 shares@ US$47.0116Common StockSEC:0001193125-26-461248:1
- 22,865 shares@ US$47.7799Common StockSEC:0001193125-26-461248:2
- 31,572 shares@ US$48.7002Common StockSEC:0001193125-26-461248:3
- 4,175 shares@ US$49.6465Common StockSEC:0001193125-26-461248:4
- 2,013 shares@ US$50.897Common StockSEC:0001193125-26-461248:5
- 1,055 shares@ US$51.90Common StockSEC:0001193125-26-461248:6
- 18,000 shares@ US$3.6452100.0% of flowCommon StockSEC:0001193125-26-290622:0
- 13,319 shares@ US$6.927765.4% of flowCommon StockSEC:0000950170-25-036321:0Canonical exit: 5 Jun 2025 (T+90)
- 37,835 shares@ US$5.8236.5% of flowCommon StockSEC:0000950170-25-035064:1Canonical exit: 3 Jun 2025 (T+90)
- 41,355 shares@ US$6.0040.5% of flowCommon StockSEC:0000950170-25-035064:2Canonical exit: 4 Jun 2025 (T+90)
- 7,491 shares@ US$6.346834.6% of flowCommon StockSEC:0000950170-25-035064:0Canonical exit: 2 Jun 2025 (T+90)
12 of 12 declarations